Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprises

Detalhes bibliográficos
Autor(a) principal: Yang, M.
Data de Publicação: 2019
Outros Autores: Bento, P., Akbar, A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10071/20096
Resumo: This research is carried out in the backdrop of increasing product quality and environmental degradation scandals associated with Chinese Pharmaceuticals in recent years. We examine the data of 125 Chinese Pharmaceuticals between 2010-2016 to investigate the impact of overall CSR (Corporate Social Responsibility) performance as well as five unique aspects of CSR performance such as shareholders, employees, customers and suppliers, environmental practices, and the society to gauge the impact of these individual dimensions on firm’s financial performance. A mixed method approach is adopted where twenty experts from the Pharmaceutical industry firstly rate the importance of different stakeholder dimensions based on a five-point Lickert scale. Subsequently, the CSR scoring system is developed by incorporating the weighted average of experts’ scores and the performance of CSR indicators obtained from the Hexun CSR rating. The firm performance is measured by Tobin’s Q, ROA, ROE, and EPS ratios. The outcome of panel based regression models reveal that CSR has a positive and significant influence on firm’s financial performance. Moreover, although all the CSR dimensions relate positively to firm performance nonetheless environmental aspect of CSR has the most profound impact on firm performance followed by customer & suppliers, and employees. However, shareholders and society dimensions have relatively lesser influence on firm performance. These results imply that Chinese Pharmaceuticals shall further optimize their CSR performance as it can not only create a favorable brand image for various stakeholders but also results in superior financial performance.
id RCAP_e4398c28463a3a9653b1e359fb1e092c
oai_identifier_str oai:repositorio.iscte-iul.pt:10071/20096
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprisesCSR dimensionsChinese pharmaceuticalsMixed-method approachFirm performanceThis research is carried out in the backdrop of increasing product quality and environmental degradation scandals associated with Chinese Pharmaceuticals in recent years. We examine the data of 125 Chinese Pharmaceuticals between 2010-2016 to investigate the impact of overall CSR (Corporate Social Responsibility) performance as well as five unique aspects of CSR performance such as shareholders, employees, customers and suppliers, environmental practices, and the society to gauge the impact of these individual dimensions on firm’s financial performance. A mixed method approach is adopted where twenty experts from the Pharmaceutical industry firstly rate the importance of different stakeholder dimensions based on a five-point Lickert scale. Subsequently, the CSR scoring system is developed by incorporating the weighted average of experts’ scores and the performance of CSR indicators obtained from the Hexun CSR rating. The firm performance is measured by Tobin’s Q, ROA, ROE, and EPS ratios. The outcome of panel based regression models reveal that CSR has a positive and significant influence on firm’s financial performance. Moreover, although all the CSR dimensions relate positively to firm performance nonetheless environmental aspect of CSR has the most profound impact on firm performance followed by customer & suppliers, and employees. However, shareholders and society dimensions have relatively lesser influence on firm performance. These results imply that Chinese Pharmaceuticals shall further optimize their CSR performance as it can not only create a favorable brand image for various stakeholders but also results in superior financial performance.MDPI2020-03-16T09:45:08Z2019-01-01T00:00:00Z20192020-03-16T09:44:22Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10071/20096eng2071-105010.3390/su11205656Yang, M.Bento, P.Akbar, A.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-09T17:56:56Zoai:repositorio.iscte-iul.pt:10071/20096Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:29:18.555071Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprises
title Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprises
spellingShingle Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprises
Yang, M.
CSR dimensions
Chinese pharmaceuticals
Mixed-method approach
Firm performance
title_short Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprises
title_full Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprises
title_fullStr Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprises
title_full_unstemmed Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprises
title_sort Does CSR Influence firm performance indicators? evidence from Chinese pharmaceutical enterprises
author Yang, M.
author_facet Yang, M.
Bento, P.
Akbar, A.
author_role author
author2 Bento, P.
Akbar, A.
author2_role author
author
dc.contributor.author.fl_str_mv Yang, M.
Bento, P.
Akbar, A.
dc.subject.por.fl_str_mv CSR dimensions
Chinese pharmaceuticals
Mixed-method approach
Firm performance
topic CSR dimensions
Chinese pharmaceuticals
Mixed-method approach
Firm performance
description This research is carried out in the backdrop of increasing product quality and environmental degradation scandals associated with Chinese Pharmaceuticals in recent years. We examine the data of 125 Chinese Pharmaceuticals between 2010-2016 to investigate the impact of overall CSR (Corporate Social Responsibility) performance as well as five unique aspects of CSR performance such as shareholders, employees, customers and suppliers, environmental practices, and the society to gauge the impact of these individual dimensions on firm’s financial performance. A mixed method approach is adopted where twenty experts from the Pharmaceutical industry firstly rate the importance of different stakeholder dimensions based on a five-point Lickert scale. Subsequently, the CSR scoring system is developed by incorporating the weighted average of experts’ scores and the performance of CSR indicators obtained from the Hexun CSR rating. The firm performance is measured by Tobin’s Q, ROA, ROE, and EPS ratios. The outcome of panel based regression models reveal that CSR has a positive and significant influence on firm’s financial performance. Moreover, although all the CSR dimensions relate positively to firm performance nonetheless environmental aspect of CSR has the most profound impact on firm performance followed by customer & suppliers, and employees. However, shareholders and society dimensions have relatively lesser influence on firm performance. These results imply that Chinese Pharmaceuticals shall further optimize their CSR performance as it can not only create a favorable brand image for various stakeholders but also results in superior financial performance.
publishDate 2019
dc.date.none.fl_str_mv 2019-01-01T00:00:00Z
2019
2020-03-16T09:45:08Z
2020-03-16T09:44:22Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10071/20096
url http://hdl.handle.net/10071/20096
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2071-1050
10.3390/su11205656
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134855184777216